0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Communicable Diseases Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: September 2024
|
Report Code: QYRE-Auto-31N13065
Home | Market Reports | Health| Nursing
Global Communicable Diseases Therapeutics Market Research Report 2023
BUY CHAPTERS

Communicable Diseases Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-31N13065
Report
September 2024
Pages:127
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Communicable Diseases Therapeutics - Market Size

The global market for Communicable Diseases Therapeutics was estimated to be worth US$ 28160 million in 2023 and is forecast to a readjusted size of US$ 68580 million by 2030 with a CAGR of 6.6% during the forecast period 2024-2030

Communicable Diseases Therapeutics - Market

Communicable Diseases Therapeutics - Market

In this report, we study the drugs for Communicable Diseases. Communicable diseases are disorders caused by organisms — such as bacteria, viruses,fungi or parasites
The Communicable Diseases Treatment market refers to the pharmaceuticals and treatments used for the management and control of infectious diseases that can be transmitted from person to person. This market includes antiviral drugs, antibiotics, vaccines, and other therapies. The Communicable Diseases Treatment market has experienced significant growth due to factors such as the increasing prevalence of infectious diseases, the emergence of new pathogens, and the need for effective treatment options. Key players in the market include pharmaceutical companies, biotechnology firms, and government healthcare agencies. Geographically, the market is diverse, with regions facing different communicable disease burdens.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Communicable Diseases Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Communicable Diseases Therapeutics by region & country, by Type, and by Application.
The Communicable Diseases Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Communicable Diseases Therapeutics.
Market Segmentation

Scope of Communicable Diseases Therapeutics - Market Report

Report Metric Details
Report Name Communicable Diseases Therapeutics - Market
Forecasted market size in 2030 US$ 68580 million
CAGR 6.6%
Forecasted years 2024 - 2030
Segment by Type:
Segment by Application
  • Hospital
  • Clinic
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novartis, Gilead, GSK, Roche, Merck, Boehringer Ingelheim, Eli Lilly, AstraZeneca, J & J, Teva, AbbVie, Bausch Health, Abbott, Sanofi, Sun Pharma, Endo, Apotex, Amneal Pharma, Torrent Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Communicable Diseases Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Communicable Diseases Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Communicable Diseases Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Communicable Diseases Therapeutics - Market size in 2030?

Ans: The Communicable Diseases Therapeutics - Market size in 2030 will be US$ 68580 million.

Who are the main players in the Communicable Diseases Therapeutics - Market report?

Ans: The main players in the Communicable Diseases Therapeutics - Market are Novartis, Gilead, GSK, Roche, Merck, Boehringer Ingelheim, Eli Lilly, AstraZeneca, J & J, Teva, AbbVie, Bausch Health, Abbott, Sanofi, Sun Pharma, Endo, Apotex, Amneal Pharma, Torrent Pharma

What are the Application segmentation covered in the Communicable Diseases Therapeutics - Market report?

Ans: The Applications covered in the Communicable Diseases Therapeutics - Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Communicable Diseases Therapeutics - Market report?

Ans: The Types covered in the Communicable Diseases Therapeutics - Market report are HIV, Influenza, TB, Malaria, Hepatitis, HPV

Recommended Reports

Infectious Disease Therapies

Disease Diagnostic Markets

Preventive Vaccines & Devices

1 Market Overview
1.1 Communicable Diseases Therapeutics Product Introduction
1.2 Global Communicable Diseases Therapeutics Market Size Forecast
1.3 Communicable Diseases Therapeutics Market Trends & Drivers
1.3.1 Communicable Diseases Therapeutics Industry Trends
1.3.2 Communicable Diseases Therapeutics Market Drivers & Opportunity
1.3.3 Communicable Diseases Therapeutics Market Challenges
1.3.4 Communicable Diseases Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Communicable Diseases Therapeutics Players Revenue Ranking (2023)
2.2 Global Communicable Diseases Therapeutics Revenue by Company (2019-2024)
2.3 Key Companies Communicable Diseases Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Communicable Diseases Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Communicable Diseases Therapeutics
2.6 Communicable Diseases Therapeutics Market Competitive Analysis
2.6.1 Communicable Diseases Therapeutics Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Communicable Diseases Therapeutics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Communicable Diseases Therapeutics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 HIV
3.1.2 Influenza
3.1.3 TB
3.1.4 Malaria
3.1.5 Hepatitis
3.1.6 HPV
3.2 Global Communicable Diseases Therapeutics Sales Value by Type
3.2.1 Global Communicable Diseases Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Communicable Diseases Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global Communicable Diseases Therapeutics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Other
4.2 Global Communicable Diseases Therapeutics Sales Value by Application
4.2.1 Global Communicable Diseases Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Communicable Diseases Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global Communicable Diseases Therapeutics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Communicable Diseases Therapeutics Sales Value by Region
5.1.1 Global Communicable Diseases Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Communicable Diseases Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global Communicable Diseases Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global Communicable Diseases Therapeutics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Communicable Diseases Therapeutics Sales Value, 2019-2030
5.2.2 North America Communicable Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Communicable Diseases Therapeutics Sales Value, 2019-2030
5.3.2 Europe Communicable Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Communicable Diseases Therapeutics Sales Value, 2019-2030
5.4.2 Asia Pacific Communicable Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Communicable Diseases Therapeutics Sales Value, 2019-2030
5.5.2 South America Communicable Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Communicable Diseases Therapeutics Sales Value, 2019-2030
5.6.2 Middle East & Africa Communicable Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Communicable Diseases Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Communicable Diseases Therapeutics Sales Value
6.3 United States
6.3.1 United States Communicable Diseases Therapeutics Sales Value, 2019-2030
6.3.2 United States Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Communicable Diseases Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Communicable Diseases Therapeutics Sales Value, 2019-2030
6.4.2 Europe Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Communicable Diseases Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Communicable Diseases Therapeutics Sales Value, 2019-2030
6.5.2 China Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Communicable Diseases Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Communicable Diseases Therapeutics Sales Value, 2019-2030
6.6.2 Japan Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Communicable Diseases Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Communicable Diseases Therapeutics Sales Value, 2019-2030
6.7.2 South Korea Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Communicable Diseases Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Communicable Diseases Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Communicable Diseases Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Communicable Diseases Therapeutics Sales Value, 2019-2030
6.9.2 India Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Communicable Diseases Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Profile
7.1.2 Novartis Main Business
7.1.3 Novartis Communicable Diseases Therapeutics Products, Services and Solutions
7.1.4 Novartis Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.1.5 Novartis Recent Developments
7.2 Gilead
7.2.1 Gilead Profile
7.2.2 Gilead Main Business
7.2.3 Gilead Communicable Diseases Therapeutics Products, Services and Solutions
7.2.4 Gilead Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.2.5 Gilead Recent Developments
7.3 GSK
7.3.1 GSK Profile
7.3.2 GSK Main Business
7.3.3 GSK Communicable Diseases Therapeutics Products, Services and Solutions
7.3.4 GSK Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.3.5 Roche Recent Developments
7.4 Roche
7.4.1 Roche Profile
7.4.2 Roche Main Business
7.4.3 Roche Communicable Diseases Therapeutics Products, Services and Solutions
7.4.4 Roche Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.4.5 Roche Recent Developments
7.5 Merck
7.5.1 Merck Profile
7.5.2 Merck Main Business
7.5.3 Merck Communicable Diseases Therapeutics Products, Services and Solutions
7.5.4 Merck Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.5.5 Merck Recent Developments
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Profile
7.6.2 Boehringer Ingelheim Main Business
7.6.3 Boehringer Ingelheim Communicable Diseases Therapeutics Products, Services and Solutions
7.6.4 Boehringer Ingelheim Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.6.5 Boehringer Ingelheim Recent Developments
7.7 Eli Lilly
7.7.1 Eli Lilly Profile
7.7.2 Eli Lilly Main Business
7.7.3 Eli Lilly Communicable Diseases Therapeutics Products, Services and Solutions
7.7.4 Eli Lilly Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.7.5 Eli Lilly Recent Developments
7.8 AstraZeneca
7.8.1 AstraZeneca Profile
7.8.2 AstraZeneca Main Business
7.8.3 AstraZeneca Communicable Diseases Therapeutics Products, Services and Solutions
7.8.4 AstraZeneca Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.8.5 AstraZeneca Recent Developments
7.9 J & J
7.9.1 J & J Profile
7.9.2 J & J Main Business
7.9.3 J & J Communicable Diseases Therapeutics Products, Services and Solutions
7.9.4 J & J Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.9.5 J & J Recent Developments
7.10 Teva
7.10.1 Teva Profile
7.10.2 Teva Main Business
7.10.3 Teva Communicable Diseases Therapeutics Products, Services and Solutions
7.10.4 Teva Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.10.5 Teva Recent Developments
7.11 AbbVie
7.11.1 AbbVie Profile
7.11.2 AbbVie Main Business
7.11.3 AbbVie Communicable Diseases Therapeutics Products, Services and Solutions
7.11.4 AbbVie Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.11.5 AbbVie Recent Developments
7.12 Bausch Health
7.12.1 Bausch Health Profile
7.12.2 Bausch Health Main Business
7.12.3 Bausch Health Communicable Diseases Therapeutics Products, Services and Solutions
7.12.4 Bausch Health Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.12.5 Bausch Health Recent Developments
7.13 Abbott
7.13.1 Abbott Profile
7.13.2 Abbott Main Business
7.13.3 Abbott Communicable Diseases Therapeutics Products, Services and Solutions
7.13.4 Abbott Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.13.5 Abbott Recent Developments
7.14 Sanofi
7.14.1 Sanofi Profile
7.14.2 Sanofi Main Business
7.14.3 Sanofi Communicable Diseases Therapeutics Products, Services and Solutions
7.14.4 Sanofi Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.14.5 Sanofi Recent Developments
7.15 Sun Pharma
7.15.1 Sun Pharma Profile
7.15.2 Sun Pharma Main Business
7.15.3 Sun Pharma Communicable Diseases Therapeutics Products, Services and Solutions
7.15.4 Sun Pharma Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.15.5 Sun Pharma Recent Developments
7.16 Endo
7.16.1 Endo Profile
7.16.2 Endo Main Business
7.16.3 Endo Communicable Diseases Therapeutics Products, Services and Solutions
7.16.4 Endo Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.16.5 Endo Recent Developments
7.17 Apotex
7.17.1 Apotex Profile
7.17.2 Apotex Main Business
7.17.3 Apotex Communicable Diseases Therapeutics Products, Services and Solutions
7.17.4 Apotex Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.17.5 Apotex Recent Developments
7.18 Amneal Pharma
7.18.1 Amneal Pharma Profile
7.18.2 Amneal Pharma Main Business
7.18.3 Amneal Pharma Communicable Diseases Therapeutics Products, Services and Solutions
7.18.4 Amneal Pharma Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.18.5 Amneal Pharma Recent Developments
7.19 Torrent Pharma
7.19.1 Torrent Pharma Profile
7.19.2 Torrent Pharma Main Business
7.19.3 Torrent Pharma Communicable Diseases Therapeutics Products, Services and Solutions
7.19.4 Torrent Pharma Communicable Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.19.5 Torrent Pharma Recent Developments
8 Industry Chain Analysis
8.1 Communicable Diseases Therapeutics Industrial Chain
8.2 Communicable Diseases Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Communicable Diseases Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Communicable Diseases Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
    Table 1. Communicable Diseases Therapeutics Market Trends
    Table 2. Communicable Diseases Therapeutics Market Drivers & Opportunity
    Table 3. Communicable Diseases Therapeutics Market Challenges
    Table 4. Communicable Diseases Therapeutics Market Restraints
    Table 5. Global Communicable Diseases Therapeutics Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Communicable Diseases Therapeutics Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Communicable Diseases Therapeutics Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Communicable Diseases Therapeutics Product Type
    Table 9. Key Companies Time to Begin Mass Production of Communicable Diseases Therapeutics
    Table 10. Global Communicable Diseases Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Communicable Diseases Therapeutics as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Communicable Diseases Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Communicable Diseases Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Communicable Diseases Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Communicable Diseases Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Communicable Diseases Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Communicable Diseases Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Communicable Diseases Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Communicable Diseases Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Communicable Diseases Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Communicable Diseases Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Communicable Diseases Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Communicable Diseases Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Communicable Diseases Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Communicable Diseases Therapeutics Sales Value by Region (2019-2024) & (%)
    Table 27. Global Communicable Diseases Therapeutics Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Communicable Diseases Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Communicable Diseases Therapeutics Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Communicable Diseases Therapeutics Sales Value, (2025-2030) & (US$ Million)
    Table 31. Novartis Basic Information List
    Table 32. Novartis Description and Business Overview
    Table 33. Novartis Communicable Diseases Therapeutics Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Novartis (2019-2024)
    Table 35. Novartis Recent Developments
    Table 36. Gilead Basic Information List
    Table 37. Gilead Description and Business Overview
    Table 38. Gilead Communicable Diseases Therapeutics Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Gilead (2019-2024)
    Table 40. Gilead Recent Developments
    Table 41. GSK Basic Information List
    Table 42. GSK Description and Business Overview
    Table 43. GSK Communicable Diseases Therapeutics Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of GSK (2019-2024)
    Table 45. GSK Recent Developments
    Table 46. Roche Basic Information List
    Table 47. Roche Description and Business Overview
    Table 48. Roche Communicable Diseases Therapeutics Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Roche (2019-2024)
    Table 50. Roche Recent Developments
    Table 51. Merck Basic Information List
    Table 52. Merck Description and Business Overview
    Table 53. Merck Communicable Diseases Therapeutics Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Merck (2019-2024)
    Table 55. Merck Recent Developments
    Table 56. Boehringer Ingelheim Basic Information List
    Table 57. Boehringer Ingelheim Description and Business Overview
    Table 58. Boehringer Ingelheim Communicable Diseases Therapeutics Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Boehringer Ingelheim (2019-2024)
    Table 60. Boehringer Ingelheim Recent Developments
    Table 61. Eli Lilly Basic Information List
    Table 62. Eli Lilly Description and Business Overview
    Table 63. Eli Lilly Communicable Diseases Therapeutics Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Eli Lilly (2019-2024)
    Table 65. Eli Lilly Recent Developments
    Table 66. AstraZeneca Basic Information List
    Table 67. AstraZeneca Description and Business Overview
    Table 68. AstraZeneca Communicable Diseases Therapeutics Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of AstraZeneca (2019-2024)
    Table 70. AstraZeneca Recent Developments
    Table 71. J & J Basic Information List
    Table 72. J & J Description and Business Overview
    Table 73. J & J Communicable Diseases Therapeutics Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of J & J (2019-2024)
    Table 75. J & J Recent Developments
    Table 76. Teva Basic Information List
    Table 77. Teva Description and Business Overview
    Table 78. Teva Communicable Diseases Therapeutics Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Teva (2019-2024)
    Table 80. Teva Recent Developments
    Table 81. AbbVie Basic Information List
    Table 82. AbbVie Description and Business Overview
    Table 83. AbbVie Communicable Diseases Therapeutics Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of AbbVie (2019-2024)
    Table 85. AbbVie Recent Developments
    Table 86. Bausch Health Basic Information List
    Table 87. Bausch Health Description and Business Overview
    Table 88. Bausch Health Communicable Diseases Therapeutics Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Bausch Health (2019-2024)
    Table 90. Bausch Health Recent Developments
    Table 91. Abbott Basic Information List
    Table 92. Abbott Description and Business Overview
    Table 93. Abbott Communicable Diseases Therapeutics Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Abbott (2019-2024)
    Table 95. Abbott Recent Developments
    Table 96. Sanofi Basic Information List
    Table 97. Sanofi Description and Business Overview
    Table 98. Sanofi Communicable Diseases Therapeutics Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Sanofi (2019-2024)
    Table 100. Sanofi Recent Developments
    Table 101. Sun Pharma Basic Information List
    Table 102. Sun Pharma Description and Business Overview
    Table 103. Sun Pharma Communicable Diseases Therapeutics Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Sun Pharma (2019-2024)
    Table 105. Sun Pharma Recent Developments
    Table 106. Endo Basic Information List
    Table 107. Endo Description and Business Overview
    Table 108. Endo Communicable Diseases Therapeutics Products, Services and Solutions
    Table 109. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Endo (2019-2024)
    Table 110. Endo Recent Developments
    Table 111. Apotex Basic Information List
    Table 112. Apotex Description and Business Overview
    Table 113. Apotex Communicable Diseases Therapeutics Products, Services and Solutions
    Table 114. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Apotex (2019-2024)
    Table 115. Apotex Recent Developments
    Table 116. Amneal Pharma Basic Information List
    Table 117. Amneal Pharma Description and Business Overview
    Table 118. Amneal Pharma Communicable Diseases Therapeutics Products, Services and Solutions
    Table 119. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Amneal Pharma (2019-2024)
    Table 120. Amneal Pharma Recent Developments
    Table 121. Torrent Pharma Basic Information List
    Table 122. Torrent Pharma Description and Business Overview
    Table 123. Torrent Pharma Communicable Diseases Therapeutics Products, Services and Solutions
    Table 124. Revenue (US$ Million) in Communicable Diseases Therapeutics Business of Torrent Pharma (2019-2024)
    Table 125. Torrent Pharma Recent Developments
    Table 126. Key Raw Materials Lists
    Table 127. Raw Materials Key Suppliers Lists
    Table 128. Communicable Diseases Therapeutics Downstream Customers
    Table 129. Communicable Diseases Therapeutics Distributors List
    Table 130. Research Programs/Design for This Report
    Table 131. Key Data Information from Secondary Sources
    Table 132. Key Data Information from Primary Sources
    Table 133. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Communicable Diseases Therapeutics Product Picture
    Figure 2. Global Communicable Diseases Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Communicable Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 4. Communicable Diseases Therapeutics Report Years Considered
    Figure 5. Global Communicable Diseases Therapeutics Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Communicable Diseases Therapeutics Revenue in 2023
    Figure 7. Communicable Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. HIV Picture
    Figure 9. Influenza Picture
    Figure 10. TB Picture
    Figure 11. Malaria Picture
    Figure 12. Hepatitis Picture
    Figure 13. HPV Picture
    Figure 14. Global Communicable Diseases Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Communicable Diseases Therapeutics Sales Value Market Share by Type, 2023 & 2030
    Figure 16. Product Picture of Hospital
    Figure 17. Product Picture of Clinic
    Figure 18. Product Picture of Other
    Figure 19. Global Communicable Diseases Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 20. Global Communicable Diseases Therapeutics Sales Value Market Share by Application, 2023 & 2030
    Figure 21. North America Communicable Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 22. North America Communicable Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 23. Europe Communicable Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 24. Europe Communicable Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 25. Asia Pacific Communicable Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 26. Asia Pacific Communicable Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 27. South America Communicable Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 28. South America Communicable Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 29. Middle East & Africa Communicable Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 30. Middle East & Africa Communicable Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 31. Key Countries/Regions Communicable Diseases Therapeutics Sales Value (%), (2019-2030)
    Figure 32. United States Communicable Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 33. United States Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 34. United States Communicable Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 35. Europe Communicable Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 36. Europe Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 37. Europe Communicable Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 38. China Communicable Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 39. China Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 40. China Communicable Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 41. Japan Communicable Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 42. Japan Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 43. Japan Communicable Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 44. South Korea Communicable Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 45. South Korea Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 46. South Korea Communicable Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 47. Southeast Asia Communicable Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 48. Southeast Asia Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 49. Southeast Asia Communicable Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 50. India Communicable Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 51. India Communicable Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 52. India Communicable Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 53. Communicable Diseases Therapeutics Industrial Chain
    Figure 54. Communicable Diseases Therapeutics Manufacturing Cost Structure
    Figure 55. Channels of Distribution (Direct Sales, and Distribution)
    Figure 56. Bottom-up and Top-down Approaches for This Report
    Figure 57. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

RELATED REPORTS

Global Persistent Epithelial Defect Management Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-2O19977
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Intelligent Elderly Care Equipment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E8132
Wed Sep 17 00:00:00 UTC 2025

Add to Cart

Global Radiation Monitoring Systems Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-23I7304
Tue Sep 16 00:00:00 UTC 2025

Add to Cart

Global Ophthalmology Homeopathic Products Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-8T5982
Tue Sep 16 00:00:00 UTC 2025

Add to Cart